• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Ischemic Stroke - Pipeline Review, H2 2012 Product Image

Ischemic Stroke - Pipeline Review, H2 2012

  • ID: 2298732
  • October 2012
  • 164 pages
  • Global Markets Direct

Ischemic Stroke – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Ischemic Stroke - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemic Stroke. Ischemic Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ischemic Stroke.
- A review of the Ischemic Stroke products under development by companies and universities/research institutes based READ MORE >

2
List of Tables 9
List of Figures 10
Introduction 11
REPORT COVERAGE 11
Ischemic Stroke Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Ischemic Stroke 13
Ischemic Stroke Therapeutics under Development by Companies 15
Ischemic Stroke Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 22
Comparative Analysis 22
Mid Clinical Stage Products 23
Comparative Analysis 23
Early Clinical Stage Products 24
Comparative Analysis 24
Pre-Clinical Stage Products 25
Comparative Analysis 25
Ischemic Stroke Therapeutics – Products under Development by Companies 26
Ischemic Stroke Therapeutics – Products under Investigation by Universities/Institutes 28
Companies Involved in Ischemic Stroke Therapeutics Development 30
Sanofi-Aventis 30
Daiichi Sankyo Company, Ltd 31
Aldagen, Inc. 32
H Lundbeck A/S 33
Mitsubishi Tanabe Pharma Corporation 34
Pfizer Inc. 35
Celgene Corporation 36
Neuralstem, Inc. 37
WhanIn Pharmaceutical Co., Ltd. 38
Pluristem Therapeutics Inc. 39
Stem Cell Therapeutics Corp. 40
NeuroVive Pharmaceutical AB 41
D-Pharm Ltd. 42
BioMAS Ltd. 43
Remedy Pharmaceuticals, Inc. 44
Angion Biomedica Corp. 45
Stemedica Cell Technologies, Inc. 46
M's Science Corporation 47
Thrombotech Technologies, Ltd. 48
Gaia BioPharma Limited 49
Ischemic Stroke – Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
Lu-AA24493 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
desmoteplase - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
desmoteplase - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PDA-001 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MP-124 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
DP-b99 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
GAI-122 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
BB-3 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
NTx-265 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
SA-4503 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
minocycline - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Activase + Integrilin - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
donepezil hydrochloride - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
AS-101 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
prasugrel hydrochloride - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
deferoxamine - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Clopidogrel + Aspirin - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
alteplase - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Argatroban + Alteplase - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
fluoxetine - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
darbepoetin alfa - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Caffeinol + Hypothermia - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
PF-03049423 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Human Serum Albumin - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
alteplase - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
donepezil hydrochloride - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
argatroban - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
GM-602 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
SAR-126119 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Low-Dose Recombinant Tissue Plasminogen Activator - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
NVP-014 - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Tissue Plasminogen Activator + Edaravone - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
G-CSF - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
Minocycline - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
WIB-801C - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
Privigen - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
NT-KC-005 - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
alteplase - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
3K3A-APC - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
Allogenic Mesenchymal Stem Cells From Adipose Tissue - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
Umbilical Cord Blood CD34+ Stem Cell - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
Ischemic Stroke Therapeutics – Drug Profile Updates 136
Ischemic Stroke Therapeutics – Discontinued Products 150
Ischemic Stroke Therapeutics - Dormant Products 152
Ischemic Stroke – Product Development Milestones 155
Featured News & Press Releases 155
Oct 02, 2012: Athersys Reports On Progress In Phase II Study Of MultiStem For Ischemic Stroke 155
Sep 27, 2012: Neuralstem Receives Approval To Commence Ischemic Stroke Trial In China 155
Sep 25, 2012: NICE Recommends Boehringer Ingelheim's Alteplase For Treatment Of Acute Ischemic Stroke 156
Sep 11, 2012: ReNeuron Submits Clinical Trial Application For ReN001 In UK 157
Sep 11, 2012: ReNeuron Submits Clinical Trial Application For ReN009 In UK 158
Aug 24, 2012: NICE Draft Guidance Recommends Boehringer Ingelheim's Alteplase For Treatment Of Stroke 159
Aug 23, 2012: NICE Issues Draft Guidance On Use Of Boehringer Ingelheim's Actilyse To Reduce Long Term Impact Of Strokes 159
Aug 21, 2012: University Of Glasgow Study Demonstrates Ability Of Oxycyte To Supply Oxygen To Critical Penumbral Tissue In Acute Ischemic Stroke 160
Aug 14, 2012: ReNeuron Receives DSMB Clearance To Progress To Higher Dose In Stem Cell Study Of ReN001 In Disabled Stroke Patients 161
Aug 13, 2012: Laureate Biopharma And ZZ Biotech's Partnership Produces New Stroke Drug 162
Appendix 163
Methodology 163
Coverage 163
Secondary Research 163
Primary Research 163
Expert Panel Validation 163
Contact Us 164
Disclaimer 164

List of Tables
Number of Products Under Development for Ischemic Stroke, H2 2012 13
Products under Development for Ischemic Stroke – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2012 19
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 20
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 21
Comparative Analysis by Late Stage Development, H2 2012 22
Comparative Analysis by Mid Clinical Stage Development, H2 2012 23
Comparative Analysis by Early Clinical Stage Development, H2 2012 24
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 25
Products under Development by Companies, H2 2012 26
Products under Development by Companies, H2 2012 (Contd..1) 27
Products under Investigation by Universities/Institutes, H2 2012 28
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 29
Sanofi-Aventis, H2 2012 30
Daiichi Sankyo Company, Ltd, H2 2012 31
Aldagen, Inc., H2 2012 32
H Lundbeck A/S, H2 2012 33
Mitsubishi Tanabe Pharma Corporation, H2 2012 34
Pfizer Inc., H2 2012 35
Celgene Corporation, H2 2012 36
Neuralstem, Inc., H2 2012 37
WhanIn Pharmaceutical Co., Ltd., H2 2012 38
Pluristem Therapeutics Inc., H2 2012 39
Stem Cell Therapeutics Corp., H2 2012 40
NeuroVive Pharmaceutical AB, H2 2012 41
D-Pharm Ltd., H2 2012 42
BioMAS Ltd., H2 2012 43
Remedy Pharmaceuticals, Inc., H2 2012 44
Angion Biomedica Corp., H2 2012 45
Stemedica Cell Technologies, Inc., H2 2012 46
M's Science Corporation, H2 2012 47
Thrombotech Technologies, Ltd., H2 2012 48
Gaia BioPharma Limited, H2 2012 49
Assessment by Monotherapy Products, H2 2012 50
Assessment by Combination Products, H2 2012 51
Assessment by Stage and Route of Administration, H2 2012 53
Assessment by Stage and Molecule Type, H2 2012 55
Ischemic Stroke Therapeutics – Drug Profile Updates 136
Ischemic Stroke Therapeutics – Discontinued Products 150
Ischemic Stroke Therapeutics – Discontinued Products (Contd..1) 151
Ischemic Stroke Therapeutics – Dormant Products 152
Ischemic Stroke Therapeutics – Dormant Products (Contd..1) 153
Ischemic Stroke Therapeutics – Dormant Products (Contd..2) 154

List of Figures
Number of Products under Development for Ischemic Stroke, H2 2012 13
Products under Development for Ischemic Stroke – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 18
Late Stage Products, H2 2012 22
Mid Clinical Stage Products, H2 2012 23
Early Clinical Stage Products, H2 2012 24
Pre-Clinical Stage Products, H2 2012 25
Assessment by Monotherapy Products, H2 2012 50
Assessment by Combination Products, H2 2012 51
Assessment by Route of Administration, H2 2012 52
Assessment by Stage and Route of Administration, H2 2012 53
Assessment by Molecule Type, H2 2012 54
Assessment by Stage and Molecule Type, H2 2012 55

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos